People

Strategy and Policy Council

Strategy and Policy Council Membership as of February 2008:

  • Claude R. Canizares, PhD (Council Chair), VP for Research and Associate Provost, MIT
  • Tenley E. Albright, MD, Surgeon, Massachusetts General Hospital
  • Ernst Berndt, PhD, Louis E. Seley Professor of Applied Economics, MIT
  • Vijay Bhargava, PhD, Vice President, Global Head, DMPK, Novartis
  • G. Steven Burrill, CEO, Burrill & Company
  • Steven E. Caffe, MD, Global VP, Regulatory Affairs/Pharmacovigilance, Baxter Healthcare Corporation
  • Victor Dzau, MD, Chancellor for Health Affairs and President and CEO, Duke University Health System, Duke University
  • Peter Farina, PhD, CBI Distinguished Fellow, and former VP of Development, North America, Boehringer-Ingelheim
  • Mr. Fred Frank, Vice Chairman and Director, Lehman Brothers
  • Julie Gerberding, MD, MPH, Director, Centers for Disease Control and Prevention (CDC)
  • Evian Gordon, PhD, MBBch, Chairman and CEO, Brain Resource Company
  • Neil Graham, MD, Senior Vice President, Program and Portfolio Management, Vertex Pharmaceuticals
  • Sean Harper, MD, Vice President, Global Regulatory and Safety, Amgen
  • Gigi Hirsch, MD, Executive Director, Center for Biomedical Innovation, MIT
  • Howard G. Hutchinson, MD, Chief Medical Officer, AstraZeneca Pharmaceuticals
  • Thomas L. Magnanti, PhD, Institute Professor and Former Dean, School of Engineering, MIT
  • Mark McClellan, MD, PhD, Director, Engelberg Center for Health Care Reform; Senior Fellow, Economics Studies; Leonard D. Schaeffer Director's Chair in Health Policy, Brookings Institution
  • Robert Mulroy, MPPM, President and CEO, Merrimack Pharmaceuticals
  • Steven M. Paul, MD, Executive VP, Science and Technology and President, Lilly Research Laboratories, Eli Lilly and Company
  • Roger Perlmutter, MD, Executive VP for R&D, Amgen
  • Wayne Rosencranz, PhD, Business Strategy Director, External Scientific Affairs for AstraZeneca and President and Chairman of the Personalized Medicine Coalition
  • Una Ryan, PhD, OBE, President and CEO, AVANT Immunotherapeutics, Inc.
  • Phillip A. Sharp, PhD, Institute Professor, MIT
  • Anthony Sinskey, ScD, Faculty Director, CBI; Professor of Biology and Health Sciences and Technology, MIT
  • Matthew Strobeck, PhD, Senior Security Analyst, Westfield Capital Management
  • Steven R. Tannenbaum, PhD, Professor of Biological Engineering, MIT
  • Mark Trusheim, President, Co-Bio Consulting, LLC
  • Janet Woodcock, MD, Deputy Commissioner, Acting Director of the Center for Drug Evaluation and Research, and Chief Medical Officer, Food and Drug Administration